<h1 id="general-overview">General Overview</h1>

<h2 id="citation">Citation</h2>

<ol>
<li>Staerk L, Lip GY, Olesen JB, Fosb√∏l EL, Pallisgaard JL, Bonde AN, Gundlund A, Lindhardt TB, Hansen ML, Torp-Pedersen C, Gislason GH. Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. BMJ. 2015 Nov 16;351:h5876. doi: 10.1136/bmj.h5876. PubMed PMID: 26572685; PubMed Central PMCID: PMC4646074</li>
</ol>

<h2 id="objective">Objective</h2>

<p>Examine the risk of all cause mortality and hospital admission or death due-thromboembolism, major bleeding, or recurrent GI bleeding associated with restarting antithrombotic treatment after a GI bleed in patients with atrial fibrillation.</p>

<h1 id="background">Background</h1>

<ul>
<li>Atrial fibrillation is responsible for $&gt;$ 70,000 ischemic strokes each year \cite{1}</li>
<li>Anticoagulation reduces risk of ischemic stroke in patients with non-valvular atrial fibrillation \cite{2}</li>
<li>Anticoagulation increases risk for developing bleed \cite{3}</li>
<li>Gastrointestinal hemorrhage is the most common form of bleeding due-oral anticoagulation treatment in patients with atrial fibrillation \cite{4}</li>
<li>Up-50.9% of patients with atrial fibrillation do not resume therapy after GI bleed \cite{5}</li>
<li>Little data exist on whether-restart antithrombotic treatment or withhold treatment after GI bleed \cite{6}</li>
</ul>

<h1 id="methods">Methods</h1>

<h2 id="trial-design">Trial design</h2>

<p>Observational, retrospective cohort</p>

<h2 id="inclusion-criteria">Inclusion criteria</h2>

<ul>
<li>Atrial fibrillation</li>
<li>Experienced GI bleed while receiving antithrombotic therapy (vitamin K antagonist, dabigatran, rivaroxaban, aspirin, clopidogrel, prasugrel, ticagrelor)</li>
</ul>

<h2 id="exclusion-criteria">Exclusion criteria</h2>

<ul>
<li>Age $&lt;$ 30 or Age $&gt;$ 100</li>
<li>Valvular heart disease</li>
<li>Total hip or knee replacement surgery $&gt;$ 8 weeks before inclusion event</li>
<li>DVT or PE $&gt;$ 6 months before inclusion event</li>
<li>Death or thromboembolic event, major bleeding, recurrent GI bleed within 90 day after inclusion event</li>
</ul>

<h2 id="treatment-groups">Treatment groups</h2>

<ul>
<li>Single oral anticoagulant (OAC)

<ul>
<li>Vitamin K antagonist, dabigatran, rivaroxaban</li>
</ul></li>
<li>Single antiplatelet

<ul>
<li>Aspirin, clopidogrel, prasugrel, ticagrelor</li>
</ul></li>
<li>Dual or triple therapy

<ul>
<li>Oral anticoagulation, aspirin, clopidogrel, prasugrel, ticagrelor</li>
</ul></li>
</ul>

<h2 id="outcomes">Outcomes</h2>

<ul>
<li>All cause mortality</li>
<li>Admission-hospital</li>
<li>Death due-thromboembolism

<ul>
<li>Ischemic stroke, transient ischemic attack, systemic thromboembolism</li>
</ul></li>
<li>Major bleeding

<ul>
<li>Intracranial bleeding, severe bleeding from respiratory system, GI/urinary bleeding</li>
</ul></li>
<li>Recurrent GI bleed

<ul>
<li>Defined using all diagnosis codes for GI bleeding</li>
</ul></li>
</ul>

<h2 id="statistical-analysis">Statistical Analysis</h2>

<ul>
<li>Baseline characteristics were represented using means and SD</li>
<li>Independence/homogeneity of categorical variables was assessed using $\chi^2$ tests</li>
<li>Cumulative incidence of outcomes was assessed using Aalen-Johansen method</li>
<li>Time dependent Cox proportional hazards models were used-examine the risk of events during follow-up</li>
<li>Significance was determined using two-sided $\alpha$</li>
</ul>

<h1 id="results">Results</h1>

<h2 id="enrollment">Enrollment</h2>

<p>See Fig. \ref{enrollment} for patient enrollment diagram.</p>

<p><img src="flow.pdf" alt="Patient enrollment diagram.\label{enrollment}"></p>

<h2 id="baseline-characteristics">Baseline characteristics</h2>

<p>See Fig. \ref{base1} for baseline characteristics.</p>

<p><img src="baseline.pdf" alt="Patient baseline characteristics.\label{base1}"></p>

<p>See Fig. \ref{base2} for more baseline characteristics.</p>

<p><img src="demo.pdf" alt="Patient baseline characteristics continued.\label{base2}"></p>

<h2 id="outcomes">Outcomes</h2>

<p>See Fig. \ref{cum} for cumulative incidence plots for outcomes.</p>

<p><img src="cumplot.pdf" alt="Cumulative event plots.\label{cum}"></p>

<h2 id="outcome-risk">Outcome risk</h2>

<table><thead>
<tr>
<th>Outcomes</th>
<th>No of events</th>
<th>Single OAC</th>
<th>Antiplatelet</th>
<th>AC + Antiplatelet</th>
<th>ASA + P2Y$_12$</th>
</tr>
</thead><tbody>
<tr>
<td>All cause mortality</td>
<td>1730</td>
<td><strong>0.39</strong> (0.34-0.46)</td>
<td><strong>0.76</strong> (0.68-0.86)</td>
<td><strong>0.41</strong> (0.32-0.52)</td>
<td>0.88 (0.57-1.36)</td>
</tr>
<tr>
<td>Thromboembolism</td>
<td>496</td>
<td><strong>0.41</strong> (0.31-0.54)</td>
<td><strong>0.76</strong> (0.61-0.95)</td>
<td><strong>0.54</strong> (0.36-0.82)</td>
<td>0.79 (0.34-1.84)</td>
</tr>
<tr>
<td>Major bleeding</td>
<td>454</td>
<td><strong>1.37</strong> (1.06-1.77)</td>
<td>1.25 (0.96-1.62)</td>
<td>1.44 (1.00-2.08)</td>
<td>1.36 (0.54-3.43)</td>
</tr>
<tr>
<td>Recurrent GI bleed</td>
<td>216</td>
<td>1.22 (0.84-1.77)</td>
<td>1.19 (0.82-1.74)</td>
<td>1.34 (0.79-2.28)</td>
<td>0.58 (0.08-4.30)</td>
</tr>
</tbody></table>

<h1 id="discussion">Discussion</h1>

<ul>
<li>Cumulative incidence of death was high (39.9%) within 2 years of inclusion event</li>
<li>27.1% of patients did not resume antithrombotic treatment after experiencing GI bleed</li>
<li>Restarting treatment with single OAC was associated with lowest risk of all cause mortality and thromboembolism (HR 0.39 [0.34-0.46], 0.41 [0.31-0.54]) compared with non-resumption of therapy</li>
<li>None of the treatments were associated with increased risk of recurrent GI bleed</li>
</ul>

<h2 id="strengths">Strengths</h2>

<ul>
<li>Nation wide cohort of 4,602 patients with atrial fibrillation</li>
<li>Low bias data (observations recorded independent of sex, age, socioeconomic status or participation in health insurance programs)</li>
<li>Danish national prescription registry allows assessment of concomitant medications</li>
<li>Sensitivity and subgroup analyses support authors conclusions</li>
</ul>

<h2 id="limitations">Limitations</h2>

<ul>
<li>Study design does not allow assessment of causation</li>
<li>No way to directly assess adherence</li>
<li>Insufficient follow-up for late-enroll patients (under-reporting of outcomes)</li>
<li>Now way to distinguish between upper or lower GI bleed</li>
<li>Registries prevent the inclusion of INR, warfarin adherence, serum creatinine, renal function, hemoglobin or other potential confounders</li>
</ul>

<h1 id="conclusion">Conclusion</h1>

<ul>
<li>Results support resumption of antithrombotic treatment after experiencing GI bleed in patients with non-valvular atrial fibrillation</li>
<li>Single OAC associated with largest reduction in all cause mortality</li>
<li>Single OAC associated with increase in major bleeding</li>
<li>Single antiplatelet therapy associated with reduction in all cause mortality and thromboembolism</li>
<li>Single antiplatelet therapy not associated with increase in major bleed</li>
<li>None of the treatments were associated with an increased risk of recurrent GI bleed</li>
</ul>

<p>\begin{thebibliography}{1}
\bibitem{1}
Flint AC, et al. Stroke 2012;43:2788-2790</p>

<p>\bibitem{2}
Hart RG, et al. Ann Intern Med. 2007;146:857-867</p>

<p>\bibitem{3}
Cannolly SJ, et al. N Engl J Med. 2009;360:2066-2078</p>

<p>\bibitem{4}
Need citations</p>

<p>\bibitem{5}
Quereshi W, et al. Am J Cardiol 2014;113:662-8</p>

<p>\bibitem{6}
Staerk L, et al. BMJ. 2015;351:h5876
\end{thebibliography}</p>
